Delivery Order SPE2DR25D3004-SPE2DR26FXTD7
- Not listed
- The Defense Logistics Agency awarded a $2,008.80 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of December 9, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors, valued at $1,255.50, with an ultimate completion date of December 24, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement issued on December 23, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a...
- The Defense Logistics Agency awarded a delivery order valued at $1,004.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors, with an ultimate completion date of December 3, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $1,674.00 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors, with an ultimate completion date of December 4, 2025. The contract is a non-set-aside, competitively awarded delivery order with firm fixed pricing, performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for migraine prevention, representing the type...
- The Defense Logistics Agency awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors, with an ultimate completion date of September 3, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under a larger contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order valued at $3,551.65 to Amerisourcebergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors, with an ultimate completion date of January 7, 2026. This competitively awarded, firm fixed-price order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., a major pharmaceutical distributor that serves as a critical...
- The Defense Logistics Agency awarded a $1,674.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors on December 12, 2025, with an ultimate completion date of December 15, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical distributor...
- The Defense Logistics Agency awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors, valued at $2,280.70, with an ultimate completion date of December 11, 2025. This non-set-aside competitive award was issued to the vendor's corporate office location in Conshohocken, Pennsylvania, the company's headquarters. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Emgality 120 mg/mL pen injectors, valued at $1,556.10. This is a firm fixed-price delivery order with an ultimate completion date of August 29, 2025, and represents a non-competitive set-aside award. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This...
- The Defense Logistics Agency awarded a $3,348 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors on December 22, 2025, with an ultimate completion date of December 23, 2025. This firm fixed-price, competitively awarded contract is being performed at the vendor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- SPE2DR25D3004Indefinite Delivery Contract
- SPE2DR25D3004-SPE2DR26FXTD7Delivery Order
The Defense Logistics Agency awarded a $1,674 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors on January 8, 2026, with an ultimate completion date of January 9, 2026. This award was not set aside and represents a competitively awarded contract. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The vendor is a subsidiary of Cencora, Inc., which operates under the AmerisourceBergen name in the federal contracting marketplace. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at up to $999,999,999 and extending through December 2026. The parent company, Cencora, Inc., holds a primary IDC with the Defense Logistics Agency through December 31, 2031, also valued at up to $999,999,999, which serves as the comprehensive global pharmaceutical support vehicle for military healthcare programs. Emgality is a calcitonin gene-related peptide receptor antagonist used for migraine prevention, and this order fulfills federal medical supply requirements for treatment of military personnel and beneficiaries across the defense healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 1/7/26 |